Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin.
Eighty-one patients with metastatic or locally advanced colorectal cancer were treated at four oncological centers in Denmark with a regimen consisting of 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for 5 consecutive days every 4 weeks. The response rate was 21% among all 81 patients (CR 3, PR 14). The median survival was 10 months regardless of measurability, sex and location of disease. Toxicity was mild, 6 (7%) patients were excluded from the study due to gastrointestinal side-effects and 15 (19%) patients had the 5-FU dose reduced due to side-effects. The results are comparable to those of other studies using different doses of leucovorin.
Andersen
L J
LJ
Department of Oncology, Aalborg Hospital, Denmark.
Brunsgaard
N H
NH
Mejlholm
I
I
Jensen
B B
BB
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003718:Denmark; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
D002955:Leucovorin; D005472:Fluorouracil